Literature DB >> 1283585

The J-curve. The importance of gradual reduction of blood pressure.

M Luque-Otero1, C Fernandez-Pinilla.   

Abstract

Even if the treatment goal in hypertension is 'the lower the better', it is obvious that blood pressure (BP) cannot be reduced without reaching a point at which organ perfusion may become compromised and where mortality and morbidity will increase rather than decrease. In 1979, a 5-fold increase in myocardial infarction among patients whose diastolic BP was reduced to below 95mm Hg was reported. In 1987, these results were confirmed, and a J-shaped relationship between diastolic BP and death from myocardial infarction in those patients with evidence of ischaemic heart disease at entry into the trial was shown. In recent years, several studies have demonstrated this J-shaped curve with a J-point between 85 and 91mm Hg. However, all the data were obtained in retrospective analyses of a small number of patients and prospective properly designed studies are necessary before changing our treatment criteria. The Behandla Blodtryck Battre Study fulfils these criteria and preliminary results demonstrate that it is possible to achieve a further reduction in BP in well controlled hypertensive patients without increasing the incidence of side effects.

Entities:  

Mesh:

Year:  1992        PMID: 1283585     DOI: 10.2165/00003495-199200441-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  17 in total

Review 1.  Essential hypertension: hemodynamic and therapeutic changes over 20 years.

Authors:  P Lund-Johansen
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

2.  Measurements of coronary flow reserve: defining pathophysiology versus making decisions about patient care.

Authors:  F J Klocke
Journal:  Circulation       Date:  1987-12       Impact factor: 29.690

3.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

4.  Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group.

Authors: 
Journal:  J Hypertens       Date:  1985-08       Impact factor: 4.844

Review 5.  Goals of antihypertensive therapy. Is there a point beyond which pressure reduction is dangerous?

Authors:  G Berglund
Journal:  Am J Hypertens       Date:  1989-07       Impact factor: 2.689

6.  Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease?

Authors:  P C Waller; C G Isles; A F Lever; G D Murray; G T McInnes
Journal:  J Hum Hypertens       Date:  1988-06       Impact factor: 3.012

7.  Benefits and potential harm of lowering high blood pressure.

Authors:  J M Cruickshank; J M Thorp; F J Zacharias
Journal:  Lancet       Date:  1987-03-14       Impact factor: 79.321

8.  Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension.

Authors:  I M Stewart
Journal:  Lancet       Date:  1979-04-21       Impact factor: 79.321

9.  Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial.

Authors:  L Wilhelmsen; G Berglund; D Elmfeldt; T Fitzsimons; H Holzgreve; J Hosie; P E Hörnkvist; K Pennert; J Tuomilehto; H Wedel
Journal:  J Hypertens       Date:  1987-10       Impact factor: 4.844

10.  High risk of cerebro-cardiovascular morbidity in well treated male hypertensives. A retrospective study of 40-59-year-old hypertensives in a Swedish primary care district.

Authors:  L Lindholm; G Ejlertsson; B Scherstén
Journal:  Acta Med Scand       Date:  1984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.